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Aim 
The purpose of these studies was to prepare glycerol monooleate (GMO)-based cubosomes carrying the model antigen 
ovalbumin (OVA) and the adjuvant Quil-A using spray drying as preparation method as well as to in vitro characterise 
these particles. Furthermore, the cubosome formulation was loaded into polymeric microdevices, called 
microcontainers (Fig. 1a), to be further tested for the potential application in oral vaccine delivery. 
 
Methods 
The cubosomes were prepared by dissolving the GMO, Dimodan® in ethanol (5.33 w/v%) and mixing it with an aqueous 
solution of dextran (stabiliser), OVA and Quil-A (2.63, 0.52, 0.035 mg/mL, respectively). After mixing, the solution was 
spray dried on a Büchi mini spray dryer. Cryo-TEM was used to verify the cubic particle morphology after reconstitution 
of the spray dried powder. Moreover, the size and zeta potential of the particles in aqueous suspension were measured 
by dynamic light scattering. The amount of loaded OVA and release of OVA from the cubosomes in PBS at pH 7.3 was 
measured by fluorescence. SU-8 microcontainers were fabricated using two steps of photolithography1. After in vitro 
characterisation, the cubosome powder was loaded into the microcontainers using a powder embossing method2. The 
microcontainers were manually filled with cubosomes and small-angle X-ray scattering (SAXS) was performed on the 
dry particles and when hydrated in buffer at pH 6.8. Furthermore, following vaccine-loading, a lid of the pH sensitive 
polymer Eudragit® L100-55 was deposited on the cavity of the microcontainers by a spray coating system for protection 
of the vaccine formulation through the stomach.  
 
Results 
SU-8 microcontainers had an inner diameter of 220 µm and a cavity depth of 270 µm (Fig. 1a). The spray drying process 
produced cubosomes as verified by cryo-TEM (Fig. 1b) and SAXS. The particle size of the cubosomes in suspension was 
257±8 nm and the zeta potential was -18±0.6 mV. Approximately 106 µg of OVA was present in 1 mg of powder, and 
the release of OVA was fastest initially and gradually slowed down until 100 % was released within 24 h. 
Microcontainers was loaded with cubosomes and visualised using X-ray microtomography (Fig. 2). It was verified 
utilizing SAXS that the cubosomes was released from the microcontainers in buffer at pH 6.8, and the lid was deposited 
on the cubosomes-loaded microcontainers in a successful manner (Fig. 1C).   
           
Conclusion 
A dry powder of cubosomes loaded with OVA and Quil-A was produced by spray drying. After characterisation, the 
powder was loaded into microcontainers, and SAXS analyses indicated that cubosomes were released from the 
microcontainers.  
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